Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Biogen Inc (BIIB)
Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,648,008
  • Shares Outstanding, K 144,898
  • Annual Sales, $ 10,173 M
  • Annual Income, $ 3,047 M
  • 60-Month Beta 0.08
  • Price/Sales 3.33
  • Price/Cash Flow 10.67
  • Price/Book 2.30
Trade BIIB with:

Options Overview Details

View History
  • Implied Volatility 25.97% ( -0.64%)
  • Historical Volatility 27.74%
  • IV Percentile 23%
  • IV Rank 26.15%
  • IV High 44.14% on 01/05/23
  • IV Low 19.53% on 09/12/23
  • Put/Call Vol Ratio 0.52
  • Today's Volume 219
  • Volume Avg (30-Day) 2,838
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 52,068
  • Open Int (30-Day) 51,295

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 3.19
  • Number of Estimates 27
  • High Estimate 4.05
  • Low Estimate 2.75
  • Prior Year 4.05
  • Growth Rate Est. (year over year) -21.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.86 +7.90%
on 11/13/23
240.81 -1.04%
on 12/08/23
+6.61 (+2.85%)
since 11/08/23
3-Month
220.86 +7.90%
on 11/13/23
269.43 -11.55%
on 10/17/23
-20.69 (-7.99%)
since 09/08/23
52-Week
220.86 +7.90%
on 11/13/23
319.76 -25.48%
on 06/12/23
-50.80 (-17.57%)
since 12/08/22

Most Recent Stories

More News
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?

The real competitive battle is about to begin, and it will last a long time.

BIIB : 238.43 (-0.29%)
LLY : 586.80 (-0.25%)
RHHBY : 36.1580 (+1.62%)
Biogen (BIIB) Q3 2023 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2023.

BIIB : 238.43 (-0.29%)
Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company...

ALKS : 26.20 (+0.15%)
BIIB : 238.43 (-0.29%)
GILD : 78.44 (+0.50%)
JAZZ : 120.05 (+0.42%)
Light Week for Macroeconomic Numbers

Monday U.S. Featured Earnings Ryanair Holdings plc (NASDAQ:RYAAY) (Q3) Reported EPS of $7.13, ...

CJ.TO : 6.31 (+2.44%)
EFN.TO : 22.04 (+0.50%)
IVN.TO : 12.46 (+1.47%)
RYAAY : 124.61 (-1.22%)
VRTX : 350.38 (-1.01%)
NXPI : 216.50 (+2.27%)
TM : 187.03 (-1.69%)
GILD : 78.44 (+0.50%)
UBER : 61.80 (+1.34%)
DIS : 93.12 (+0.83%)
HMC : 30.52 (-0.26%)
BIIB : 238.43 (-0.29%)
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED...

BIIB : 238.43 (-0.29%)
3 Struggling Stocks Investors Shouldn't Buy on the Dip

These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.

BIIB : 238.43 (-0.29%)
SNAP : 15.06 (+2.03%)
MMM : 104.26 (+0.95%)
How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success....

AMGN : 270.69 (-0.23%)
BIIB : 238.43 (-0.29%)
GILD : 78.44 (+0.50%)
REGN : 846.11 (-0.36%)
UTHR : 241.16 (-0.38%)
Is Biogen Stock a Buy Now?

It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

BIIB : 238.43 (-0.29%)
RETA : 172.36 (+0.02%)
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

BIIB : 238.43 (-0.29%)
3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry...

BIIB : 238.43 (-0.29%)
REGN : 846.11 (-0.36%)
RETA : 172.36 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 244.98
2nd Resistance Point 242.45
1st Resistance Point 240.79
Last Price 238.43
1st Support Level 236.60
2nd Support Level 234.07
3rd Support Level 232.41

See More

52-Week High 319.76
Fibonacci 61.8% 281.98
Fibonacci 50% 270.31
Fibonacci 38.2% 258.64
Last Price 238.43
52-Week Low 220.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar